BASAGLAR will be available in the US starting after December 15, 2016* • Demonstrated sustained glucose-lowering activity over 24 hours†1 • Taken only once a day, any time of day, at the same time each day * BASAGLAR will begin shipping Dec. 15 and be available at some pharmacies starting the week of Dec. 19, with the majority of pharmacies able to order the week of Dec. 26. Specific timing on product availability may vary by location. † Study design: Phase 1 randomized, double-blind, single-dose, 2-treatment, 4-period, crossover, replicate treatment, euglycemic clamp study with 91 healthy subjects.3 Questions? Talk to your Lilly Diabetes Representative or visit BASAGLAR.com for more information. All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated. Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose- related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered. ADVERSE REACTIONS Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain. DRUG INTERACTIONS Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR. BV HCP ISI 24JUN2016 For more information, please see brief summary of Full Prescribing Information on following pages. Please see Instructions for Use included with the pen. REFERENCES 1. BASAGLAR Prescribing Information. Indianapolis, IN: Eli Lilly and Company. 2. Lantus Prescribing Information. Bridgewater, NJ: sanofi-aventis US LLC; 2015. 3. Linnebjerg H, Lam EC, Seger ME, et al. Diabetes Care. 2015;38:2226-2233. BASAGLAR® and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates, and are available by prescription only. Lantus® is a registered trademark of sanofi-aventis US LLC. PP-BV-US-0239 10/2016 PRINTED IN USA ©Lilly USA, LLC 2016. All rights reserved.
Health System Management • December 2016
To see the actual publication please follow the link above